Treatment of prehypertension: Lifestyle and/or medication

Vascular Health and Risk Management

Volumn 8, Issue 1, 2012, Pages 613-619

  Collier, Scott R ^a   Landram, Michael J ^b  

^a APPALACHIAN STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ROME FORO ITALICO   (Italy)

Author keywords

Blood pressure; Lifestyle changes; Sex differences

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEPTIN; LEPTIN RECEPTOR; PLACEBO; PRORENIN; SEX HORMONE; THIAZIDE DIURETIC AGENT;

AGE DISTRIBUTION; BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; DIETARY INTAKE; DISEASE ASSOCIATION; DRINKING BEHAVIOR; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENDOTHELIAL DYSFUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HIGH SODIUM INTAKE; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PREHYPERTENSION; PREVALENCE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTHROMBIN DEFICIENCY; PULSE PRESSURE; RACE DIFFERENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SEX CHROMOSOME; SEX DIFFERENCE; SMOKING; STRATEGIC PLANNING;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; PREHYPERTENSION; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME;

EID: 84871600633     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S29138     Document Type: Review

References (57)

1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572.
2. Fuchs FD. Prehypertension: the rationale for early drug therapy. Cardiovasc Ther. 2010;28(6):339-343.
3. Chen X, Wang Y. Tracking of blood pressure from childhood to adulthood: a systematic review and meta-regression analysis. Circulation. 2008;117(25):3171-3180.
4. Redwine KM, Daniels SR. Prehypertension in adolescents: risk and progression. J Clin Hypertens (Greenwich). 2012;14(6):360-364.
5. Redwine KM, Acosta AA, Poffenbarger T, Portman RJ, Samuels J. Development of hypertension in adolescents with pre-hypertension. J Pediatr. 2012;160(1):98-103.
6. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25(3):305-313.
7. Sandberg K, Ji H. Sex differences in primary hypertension. Biol Sex Differ. 2012;3(1):7.
8. Ji H, Zheng W, Wu X, et al. Sex chromosome effects unmasked in angiotensin II-induced hypertension. Hypertension. 2010;55(5): 1275-1282.
9. McNiece KL, Poffenbarger TS, Turner JL, Franco KD, Sorof JM, Portman RJ. Prevalence of hypertension and pre-hypertension among adolescents. J Pediatr. 2007;150(6):640-644.
10. Jago R, Harrell JS, McMurray RG, Edelstein S, El Ghormli L, Bassin S. Prevalence of abnormal lipid and blood pressure values among an ethnically diverse population of eighth-grade adolescents and screening implications. Pediatrics. 2006;117(6):2065-2073.
11. Collier SR, Curry CD, Meucci M, Welsh J, Cook CB. Metabolomic signatures of 8 weeks of play-based exercise vs. controls in overweight adolescent children. Med Sci Sports Exerc. 2012;44(5):1977.
12. Meucci M, Curry CD, Baldari C, Guidetti L, Cook C, Collier SR. Effect of Play-based Summer Break Exercise on Cardiovascular Function in Adolescents. Acta Paediatr. 2012. In Press.
13. Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. Arch Intern Med. 2004;164(19):2126-2134.
14. Pavlik VN, Hyman DJ, Doody R. Cardiovascular risk factors and cognitive function in adults 30-59 years of age (NHANES III). Neuroepidemiology. 2005;24(1-2):42-50.
15. Glasser SP, Judd S, Basile J, et al. Prehypertension, racial prevalence and its association with risk factors: Analysis of the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Am J Hypertens. 2011;24(2):194-199.
16. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354(16):1685-1697.
17. Julius S, Kaciroti N, Egan BM, Nesbitt S, Michelson EL. TROPHY study: Outcomes based on the Seventh Report of the Joint National Committee on Hypertension definition of hypertension. J Am Soc Hypertens. 2008;2(1):39-43.
18. Ji H, Menini S, Zheng W, Pesce C, Wu X, Sandberg K. Role of angiotensin-converting enzyme 2 and angiotensin(1-7) in 17beta-oestradiol regulation of renal pathology in renal wrap hypertension in rats. Exp Physiol. 2008;93(5):648-657.
19. [No authors listed]. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997.
20. [No authors listed. ACE inhibitor even prevents diabetes. Sensational HOPE study]. MMW Fortschr Med. 1999;141(39):6.German.
21. Scheen AJ. Clinical study of the month. The CAPPP study: "The Captopril Prevention Project". Rev Med Liege. 1999;54(3):197-199. French.
22. White WB. Clinical assessment of early morning blood pressure in patients with hypertension. Prev Cardiol. 2007;10(4):210-214.
23. Pimenta E, Oparil S. Prehypertension: epidemiology, consequences and treatment. Nat Rev Nephrol. 2010;6(1):21-30.
24. Staessen JA, Richart T, Wang Z, Thijs L. Implications of recently published trials of blood pressure-lowering drugs in hypertensive or high-risk patients. Hypertension. 2010;55(4):819-831.
25. Ventura HO, Lavie CJ. Antihypertensive therapy for prehypertension: relationship with cardiovascular outcomes. JAMA. 2011;305(9): 940-941.
26. Guo X, Zou L, Zhang X, et al. Prehypertension: a meta-analysis of the epidemiology, risk factors, and predictors of progression. Tex Heart Inst J. 2011;38(6):643-652
27. Friedman JM. Leptin, leptin receptors, and the control of body weight. Nutr Rev. 1998;56(2 Pt 2):s38-s46.
28. Ren J. Leptin and hyperleptinemia - from friend to foe for cardiovascular function. J Endocrinol. 2004;181(1):1-10.
29. Soderberg S, Ahren B, Jansson JH, et al. Leptin is associated with increased risk of myocardial infarction. J Intern Med. 1999;246(4): 409-418.
30. Parhami F, Tintut Y, Ballard A, Fogelman AM, Demer LL. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res. 2001;88(9):954-960.
31. Knudson JD, Dincer UD, Zhang C, et al. Leptin receptors are expressed in coronary arteries, and hyperleptinemia causes significant coronary endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2005;289(1): H48-H56.
32. Schmid DA, Wichniak A, Uhr M, et al. Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology. 2006;31(4):832-844.
33. Grassi DG. Treating prehypertension. N Engl J Med. 2006;355(4):416.
34. Ogden CL, Carroll MD, Curtin LR, Lamb MM, Flegal KM. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA. 2010;303(3):242-249.
35. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20): 1557-1562.
36. Campbell NR, McKay DW. Accurate blood pressure measurement: why does it matter? CMAJ. 1999;161(3):277-278.
37. Haynes RB, Sackett DL, Taylor DW, Gibson ES, Johnson AL. Increased absenteeism from work after detection and labeling of hypertensive patients. N Engl J Med. 1978;299(14):741-744.
38. Mainous AG 3rd, Everett CJ, Liszka H, King DE, Egan BM. Prehypertension and mortality in a nationally representative cohort. Am J Cardiol. 2004;94(12):1496-1500.
39. Whelton PK, He J, Appel LJ, et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA. 2002;288(15):1882-1888.
40. White WB. Smoking-related morbidity and mortality in the cardiovascular setting. Prev Cardiol. 2007;10(2 Suppl 1):1-4.
41. Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med. 2004;116(10): 682-692.
42. Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology. Circulation. 2003;107(24):3109-3116.
43. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395): 1527-1535.
44. Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med. 2004;164(13):1427-1436.
45. Green DJ. Exercise training as vascular medicine: direct impacts on the vasculature in humans. Exerc Sport Sci Rev. 2009;37(4):196-202.
46. Hedayati SS, Elsayed EF, Reilly RF. Non-pharmacological aspects of blood pressure management: what are the data? Kidney Int. 2011;79(10): 1061-1070.
47. Collier SR, Frechette V, Sandberg K, et al. Sex differences in resting hemodynamics and arterial stiffness following 4 weeks of resistance versus aerobic exercise training in individuals with pre-hypertension to stage 1 hypertension. Biol Sex Differ. 2011;2(1):9.
48. Collier SR, Kanaley JA, Carhart R Jr, et al. Effect of 4 weeks of aerobic or resistance exercise training on arterial stiffness, blood flow and blood pressure in pre- and stage-1 hypertensives. J Hum Hypertens. 2008;22(10):678-686.
49. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2002;136(7):493-503.
50. Kelley GA, Kelley KS. Progressive resistance exercise and resting blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2000;35(3):838-843.
51. Collier SR, Diggle MD, Heffernan KS, Kelly EE, Tobin MM, Fernhall B. Changes in arterial distensibility and flow-mediated dilation after acute resistance vs aerobic exercise. J Strength Cond Res. 2010;24(10):2846-2852.
52. Stevens VJ, Corrigan SA, Obarzanek E, et al. Weight loss intervention in phase 1 of the Trials of Hypertension Prevention. The TOHP Collaborative Research Group. Arch Intern Med. 1993;153(7):849-858.
53. Elmer PJ, Grimm R Jr, Laing B, et al. Lifestyle intervention: results of the Treatment of Mild Hypertension Study (TOMHS). Prev Med. 1995;24(4):378-388.
54. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344(1):3-10.
55. No authors listed]. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med. 1997;157(6):657-667.
56. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336(16):1117-1124.
57. Hooper M. What do you think is a non-disease? Diet, lifestyle, exercise, spirituality, and the search for meaning are ignored at our peril. BMJ. 2002;324(7342):912.